The Latest Medical News

A Summary of The Latest Medical News: **Twice-Yearly Lenacapavir: A Landmark in HIV Prevention** The World Health Organization (WHO) has released new guidelines recommending the use of injectable lenacapavir twice a year as a **breakthrough option for HIV prevention**[3]. **Clinical Trials Show Near-Complete Protection** Recent major studies, known as the PURPOSE 1 and PURPOSE 2 trials, found that a twice-yearly shot of lenacapavir resulted in nearly 100% protection against new HIV infections in participants of all genders, with more than 99.9% remaining HIV-negative during the studies[1][2]. In people aged 16-25, researchers reported zero new HIV infections in the PURPOSE 1 trial, and only two cases in PURPOSE 2 among those who received lenacapavir[4]. **A Game-Changer for High-Risk Groups** Lenacapavir's long-acting injectable formulation offers a powerful alternative to daily pills or more frequent injections, addressing common barriers like maintaining a daily medication schedule and social stigma tied to HIV prevention[1][3]. Experts emphasize that this expands options for people facing difficulties with current pre-exposure prophylaxis (PrEP) routines[2][3]. **Eligibility and Access** Anyone at risk for HIV, regardless of gender or sexual practices, is eligible for lenacapavir. This marks an improvement over older drugs with usage restrictions based on specific risk exposures[2][4]. Implementation efforts will focus on making this innovation accessible in communities most in need, as broad adoption and supportive infrastructure are crucial for maximal impact[1][3]. **FDA and Global Endorsement** In June 2025, the FDA approved lenacapavir as a twice-yearly PrEP option for both adults and adolescents at risk of HIV, following the compelling clinical data[1][4]. The WHO has stressed the importance of rapidly expanding global access, calling lenacapavir “the next best thing” to an HIV vaccine for prevention[3]. **How Lenacapavir Works** Lenacapavir is a novel capsid inhibitor that disrupts multiple stages of the HIV lifecycle, providing unique protection compared to previous classes of antiretroviral drugs[4][5]. For those living with HIV, it continues to be used in combination therapies for multi-drug-resistant cases, while for prevention it is used as a single agent with the recommendation to continue practicing safe sex, as it does not prevent other sexually transmitted infections[2][4][5]. **A New Era in HIV Prevention** With only two injections per year, lenacapavir stands out as one of the most promising advances in HIV prevention since the epidemic began, holding the potential to significantly reduce new infections worldwide[1][2][3]. Help with your insurance? https://tally.so/r/n012P9